PLoS One:对HBV有免疫性可减少糖尿病风险

2015-11-07 seven L 译 MedSci原创

肝脏在人体代谢中起着不可代替的作用。先前有研究表明,肝脏疾患会增加糖尿病风险。目前已知的HCV感染就显著增加糖尿病风险。不过HBV与糖尿病之间有没有类似关系仍不知道。研究者进行了一项横断面研究,将糖尿病定义为:空腹血糖≥7.0 mmol/L,餐后2小时血糖 ≥11.1 mmol/L或HbA1c ≥ 47.5 mmol/mol (6.5%)。通过参与者自我报道和HBV相关血清学检查获取参与者疫苗情况

肝脏在人体代谢中起着不可代替的作用。先前有研究表明,肝脏疾患会增加糖尿病风险。目前已知的HCV感染就显著增加糖尿病风险。不过HBV与糖尿病之间有没有类似关系仍不知道。

研究者进行了一项横断面研究,将糖尿病定义为:空腹血糖≥7.0 mmol/L,餐后2小时血糖 ≥11.1 mmol/L或HbA1c ≥ 47.5 mmol/mol (6.5%)。通过参与者自我报道和HBV相关血清学检查获取参与者免疫情况。

该研究共纳入了15,316名患者,基于血清学检查有 2,320名参与者对乙肝病毒有免疫性。 4,063名参与者接种了HBV疫苗,不过疫苗接种成功率只有39%。

研究数据显示HBV疫苗与糖尿病之间没有相关性(OR: 1.08, 95%CI: 0.96–1.23)。对HBV具有免疫性的血清学证据可以减少糖尿病风险(0.75, 95%CI: 0.62–0.90)。成功接种HBV疫苗也可以减少糖尿病风险(0.67, 95%CI: 0.52–0.84)。

研究结果表明,虽然成功接种HBV疫苗可以减少33%的糖尿病风险,不过对HBV疫苗和糖尿病的关系还需要更多的前瞻性研究。

原始出处:


 Jean Huang ,Horng-Yih Ou,et al.The Impact of Hepatitis B Vaccination Status on the Risk of Diabetes, Implicating Diabetes Risk Reduction by Successful Vaccination.PLoS One.October 28, 2015


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789731, encodeId=2e4e1e8973111, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Dec 05 19:29:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836606, encodeId=5e3f1836606df, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 06 08:29:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52281, encodeId=31785228182, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 22:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51074, encodeId=9ac4510e4b9, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Jan 02 00:25:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50248, encodeId=230250248f9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 15:49:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789731, encodeId=2e4e1e8973111, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Dec 05 19:29:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836606, encodeId=5e3f1836606df, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 06 08:29:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52281, encodeId=31785228182, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 22:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51074, encodeId=9ac4510e4b9, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Jan 02 00:25:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50248, encodeId=230250248f9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 15:49:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-08-06 klivis
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789731, encodeId=2e4e1e8973111, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Dec 05 19:29:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836606, encodeId=5e3f1836606df, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 06 08:29:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52281, encodeId=31785228182, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 22:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51074, encodeId=9ac4510e4b9, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Jan 02 00:25:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50248, encodeId=230250248f9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 15:49:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-01-05 xyfg98

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1789731, encodeId=2e4e1e8973111, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Dec 05 19:29:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836606, encodeId=5e3f1836606df, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 06 08:29:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52281, encodeId=31785228182, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 22:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51074, encodeId=9ac4510e4b9, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Jan 02 00:25:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50248, encodeId=230250248f9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 15:49:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-01-02 xyfg98

    值得关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1789731, encodeId=2e4e1e8973111, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Dec 05 19:29:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836606, encodeId=5e3f1836606df, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 06 08:29:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52281, encodeId=31785228182, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 22:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51074, encodeId=9ac4510e4b9, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sat Jan 02 00:25:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50248, encodeId=230250248f9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 15:49:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-29 xyfg98

    0

相关资讯

2015新版《美国慢性HBV感染治疗流程》公布

2015年7月15日,Clin Gastroenterol Hepatol在线发表了新版《美国慢性HBV感染治疗流程》。负责该治疗流程修订的美国肝病专家小组组长、迈阿密大学医学院Martin教授介绍道:“目前,慢性乙型肝炎(CHB)仍然是在包括美国的全世界范围内的一个重要的公共卫生问题。2004年,美国肝病专家小组于制定了首个用于CHB管理的治疗流程,随后在2006年和2008年分别进行了更新。自

Gut:HBV患者血清dlDNA比例的增加与肝病的进展有关

Gut:HBV患者血清dlDNA比例的增加与肝病的进展有关HBV具有两种形式的基因组,松弛环状DNA(rcDNA)和复式线状DNA(dlDNA)。研究表明,与rcDNA相比,dlDNA更常见整合至宿主细胞染色体中,并有致癌的倾向。然而,相对于总的HBV DNA,dlDNA的比例以及其临床意义仍有待研究。基于 rcDNA 和dlDNA之间结构的差异,研究人员开发出一种肽核酸(PNA)介导的实时定量P

Nat Med:揭示乙肝难愈之谜

由伦敦大学学院(UCL)领导的一项新研究揭示,乙型肝炎通过刺激一些过程夺去了机体免疫细胞发挥功能必需的关键营养物质。研究人员将他们的结果发布在5月11日的《自然医学》(Nature Medicine)杂志上。这项研究工作有助于解释一旦乙型肝炎病毒(HBV)在肝脏中建立感染,免疫系统变无法控制这种感染的原因,并为沿着这条路开发出潜在的治愈性疗法提供了一个靶点。此外,研究还为我们提供了一些有关控制免疫

Ann Intern Med:男男做爱,除了HIV,HBV感染率也很高

男人与男人做爱 (男男性行为者)(MSM)不仅HIV感染风险高,HBV感染风险也不低。 关于对HIV感染的男性、HIV未感染但同男人做爱的男性(MSM),进行高效抗逆转录病毒治疗 (HAART)对HBV感染发生率的影响的研究目前还没有。研究者对MSM(HIV感染者或高风险者)进行了一项观察性队列研究。纳入了2375名未感染HBV的MSM对象,以探究MSM人群在HAART治疗前和治疗时HBV发生情况

APASL乙型肝炎指南更新版解读

我国HBV感染者总人口为9300万,其中需要治疗的慢性乙型肝炎患者共计3000万,700万为急需治疗的严重活动性慢性乙型肝炎患者。因此,大量患者处于疾病进展高风险。过去十多年来,有效的抗病毒药物的上市,使得临床医生和慢性乙型肝炎患者共同进入到积极抗击HBV的时代,并在实践中证明了有效的抗HBV治疗可以降低疾病进展至肝硬化、肝细胞肝癌(HCC)的风险。核苷(酸)类似物(NA)和干扰素作为两大类被

Hepatology:替诺福韦酯能降低乙肝孕妈妈后代乙肝传染(PreMIT研究)

乙肝孕妇在中国并不少见,很多孕妇及家属都会担心其宫内胎儿的情况。目前替诺福韦酯(TDF)在临床上对于普通人群应用较广,并且效果得到肯定。其具有抑制乙型肝炎病毒(HBV)复制的作用,同时可以在一定程度能降低体内相关转氨酶水平,起到保护肝脏的作用。但是目前关于替诺福韦酯(TDF)在孕妇中的运用、对于减少乙型肝炎病毒(HBV)垂直传播的有效性和安全性并不明确。